Companies › Aesculap Biologics
1 active drug program in 2 registered trials: 2 Phase 3; Other; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NOVOCART 3D Matrix associated autologous chondrocyte implant | – | Phase 3 | Articular Cartilage of the Femoral Condyle Between 2-6cm2; Articular Cartilage Defect | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT01957722 | NOVOCART 3D | Phase 3 | Articular Cartilage of the Femoral Condyle Between 2-6cm2 | Other | Dec 2027 |
| NCT03219307 | NOVOCART 3D | Phase 3 | Articular Cartilage Defect | Other | Jan 2029 |
No annotated target.
–
Metcela OHB Pediatrics CoNextions Medical ULURU DiscGenics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.